Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Canbridge Pharmaceuticals's earnings before interest and taxes (EBIT) for the
six
months ended in Dec. 2025 was HK$-48.56 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$18.12 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Canbridge Pharmaceuticals's annualizedROC % for the quarter that ended in Dec. 2025 was -100.15%.
Canbridge Pharmaceuticals's annualizedROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -14,251.80%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Canbridge Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 1.83%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Canbridge Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canbridge Pharmaceuticals EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Canbridge Pharmaceuticals's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$18.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Canbridge Pharmaceuticals (HKSE:01228) has a EBIT of HK$18.12 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Canbridge Pharmaceuticals.
Is Canbridge Pharmaceuticals' EBIT too high?
Canbridge Pharmaceuticals' current EBIT is HK$18.12 Mil. Overall, Canbridge Pharmaceuticals has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canbridge Pharmaceuticals' EBIT compare to VRTX and REGN?
Canbridge Pharmaceuticals' EBIT of HK$18.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Canbridge Pharmaceuticals. Canbridge Pharmaceuticals's current EBIT is HK$18.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canbridge Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Canbridge Pharmaceuticals (HKSE:01228) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.38, compared to a current price of HK$2.05 — trading 439.5% above its estimated fair value. The current EBIT is HK$18.12 Mil. Canbridge Pharmaceuticals' overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Canbridge Pharmaceuticals (HKSE:01228), the current EBIT is HK$18.12 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canbridge Pharmaceuticals (HKSE:01228) Overvalued in 2026?
Based on GuruFocus' analysis, Canbridge Pharmaceuticals stock appears to be overvalued.
The current stock price of HK$2.05 is trading 439.5% above its estimated GF Value™ of HK$0.38.
GuruFocus considers Canbridge Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for HKSE:01228:
EBIT: HK$18.12 Mil
GF Value™: HK$0.38 vs. price of HK$2.05 (439.5% above fair value)
No single metric tells the full story. See the HKSE:01228 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.
48GF Score
Get the complete analysis for HKSE:01228
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01228 has been successfully added to your 
